Genome Web Breaking News
- Illumina Expands IP Offer to Help Save PacBio Deal as Oxford Nanopore Cries Foul
- Host Expression Provides Treatment Response Clues in Cutaneous Leishmaniasis
- GenapSys Raises $90M in Series C Round, Launches Sequencer in US
- Beckman Coulter, IncellDx Form Cancer Assay Promotion Agreement
- T2 Biosystems Gets CE Mark for Direct-From-Blood Antimicrobial Resistance Panel
Stat
- STAT Plus: A bold prediction: Machine learning will yield new drug candidates within three years
- STAT Plus: ‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation
- STAT Plus: Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’
- STAT Plus: Pharmalittle: Trump and senators push for drug prices in TV ads; Sanofi looks to spin off consumer business
- Longtime cancer researcher Charles Sawyers named first STAT Biomedical Innovation Award winner
NYT science news
- A Dance That Stops 2 of Neptune’s Moons From Colliding
- A Wet Year Causes Farm Woes Far Beyond the Floodplains
- Oxygen on Mars Adds to Atmospheric Mysteries
- Trump’s F.D.A. Nominee Sidesteps Questions About Banning Flavored Vaping Products
- Fossils Provide Clues to When Snakes Still Had Use for a Pair of Legs
Xconomy news
- Ex-Novartis Cell & Gene Therapy Exec Chou Joins Aruvant as CEO
- Relay Therapeutics Names Ben Wolf Chief Medical Officer
- Alnylam Gets Quick FDA OK for Second RNAi Rare Disease Drug
- Twist Bioscience Promotes Patrick Finn to Chief Commercial Officer
- Kronos Bio Appoints Jorge DiMartino as Its Chief Medical Officer
Fierce Biotech
- GenapSys launches tabletop DNA sequencer alongside $90M VC haul
- LivaNova to drop TMVR plans in global heart valve restructuring
- AbbVie doubles down on Harpoon with $50M option on BCMA drug
- EuroBiotech Report—Bayer's phase 3 success, U.K. trial investment, EU fund, MorphoSys and Tissium
- EuroBiotech: More Articles of Note
Fierce Medical Devices
- GenapSys launches tabletop DNA sequencer alongside $90M VC haul
- LivaNova to drop TMVR plans in global heart valve restructuring
- FDA urged to probe naltrexone implant tests on prison inmates
- FDA discloses patient deaths, safety reports from recalled balloon heart pumps
- Truvian nets $27M to build its comprehensive benchtop blood testing machine